Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com 4 years ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com 4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com 4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@techcrunch.com 4 years ago
What tech gets right about healthcare
@xconomy.com 4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@stanleychen0402 5 years ago
Feb.26,2019 Article : both #Medicare and #healthcare are curing all of us #Heath Source ref. #AI #robotics #robot #AR #VR #datatransformation #DataScience #biotech #healthcare #MedicareForAll @fklivestolearn @kashthefuturist @Ronald_vanLoon @jdelacruz_IoT @NeurozoInnovat1 https://t.co/a5AgZbtn95
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com 5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com 5 years ago
Trump Plan Ties Medicare Drug Prices to Cheaper Foreign Ones
@xconomy.com 5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com 5 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com 5 years ago
Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up